Cargando…
Generation of pancreatic β cells for treatment of diabetes: advances and challenges
Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are considered attractive sources of pancreatic β cells and islet organoids. Recently, several reports presented that hESC/iPSC-derived cells enriched with specific transcription factors can form glucose-responsive insulin-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310974/ https://www.ncbi.nlm.nih.gov/pubmed/30594258 http://dx.doi.org/10.1186/s13287-018-1099-3 |
_version_ | 1783383525080170496 |
---|---|
author | Shahjalal, Hussain Md. Abdal Dayem, Ahmed Lim, Kyung Min Jeon, Tak-il Cho, Ssang-Goo |
author_facet | Shahjalal, Hussain Md. Abdal Dayem, Ahmed Lim, Kyung Min Jeon, Tak-il Cho, Ssang-Goo |
author_sort | Shahjalal, Hussain Md. |
collection | PubMed |
description | Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are considered attractive sources of pancreatic β cells and islet organoids. Recently, several reports presented that hESC/iPSC-derived cells enriched with specific transcription factors can form glucose-responsive insulin-secreting cells in vitro and transplantation of these cells ameliorates hyperglycemia in diabetic mice. However, the glucose-stimulated insulin-secreting capacity of these cells is lower than that of endogenous islets, suggesting the need to improve induction procedures. One of the critical problems facing in vivo maturation of hESC/iPSC-derived cells is their low survival rate after transplantation, although this rate increases when the implanted pancreatic cells are encapsulated to avoid the immune response. Several groups have also reported on the generation of hESC/iPSC-derived islet-like organoids, but development of techniques for complete islet structures with the eventual generation of vascularized constructs remains a major challenge to their application in regenerative therapies. Many issues also need to be addressed before the successful clinical application of hESC/iPSC-derived cells or islet organoids. In this review, we summarize advances in the generation of hESC/iPSC-derived pancreatic β cells or islet organoids and discuss the limitations and challenges for their successful therapeutic application in diabetes. |
format | Online Article Text |
id | pubmed-6310974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63109742019-01-07 Generation of pancreatic β cells for treatment of diabetes: advances and challenges Shahjalal, Hussain Md. Abdal Dayem, Ahmed Lim, Kyung Min Jeon, Tak-il Cho, Ssang-Goo Stem Cell Res Ther Review Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are considered attractive sources of pancreatic β cells and islet organoids. Recently, several reports presented that hESC/iPSC-derived cells enriched with specific transcription factors can form glucose-responsive insulin-secreting cells in vitro and transplantation of these cells ameliorates hyperglycemia in diabetic mice. However, the glucose-stimulated insulin-secreting capacity of these cells is lower than that of endogenous islets, suggesting the need to improve induction procedures. One of the critical problems facing in vivo maturation of hESC/iPSC-derived cells is their low survival rate after transplantation, although this rate increases when the implanted pancreatic cells are encapsulated to avoid the immune response. Several groups have also reported on the generation of hESC/iPSC-derived islet-like organoids, but development of techniques for complete islet structures with the eventual generation of vascularized constructs remains a major challenge to their application in regenerative therapies. Many issues also need to be addressed before the successful clinical application of hESC/iPSC-derived cells or islet organoids. In this review, we summarize advances in the generation of hESC/iPSC-derived pancreatic β cells or islet organoids and discuss the limitations and challenges for their successful therapeutic application in diabetes. BioMed Central 2018-12-29 /pmc/articles/PMC6310974/ /pubmed/30594258 http://dx.doi.org/10.1186/s13287-018-1099-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Shahjalal, Hussain Md. Abdal Dayem, Ahmed Lim, Kyung Min Jeon, Tak-il Cho, Ssang-Goo Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title | Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title_full | Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title_fullStr | Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title_full_unstemmed | Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title_short | Generation of pancreatic β cells for treatment of diabetes: advances and challenges |
title_sort | generation of pancreatic β cells for treatment of diabetes: advances and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310974/ https://www.ncbi.nlm.nih.gov/pubmed/30594258 http://dx.doi.org/10.1186/s13287-018-1099-3 |
work_keys_str_mv | AT shahjalalhussainmd generationofpancreaticbcellsfortreatmentofdiabetesadvancesandchallenges AT abdaldayemahmed generationofpancreaticbcellsfortreatmentofdiabetesadvancesandchallenges AT limkyungmin generationofpancreaticbcellsfortreatmentofdiabetesadvancesandchallenges AT jeontakil generationofpancreaticbcellsfortreatmentofdiabetesadvancesandchallenges AT chossanggoo generationofpancreaticbcellsfortreatmentofdiabetesadvancesandchallenges |